Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Articles published by Zetagen Therapeutics, Inc.

News headline image
Zetagen Therapeutics Presents Phase 2a Results at ASCO for Investigational ZetaMet™ (Zeta BC 003) in Metastatic Breast Cancer Patients with Lytic Bone Lesions
From Zetagen Therapeutics, Inc.
Via Business Wire
News headline image
Zetagen Therapeutics Closes Oversubscribed Series B1 Round on Strength of Promising Phase 2a Data and Compelling Pipeline
From Zetagen Therapeutics, Inc.
Via Business Wire
News headline image
Zetagen Therapeutics to Present Promising Preclinical Data at SABCS: Zeta-BC-007 Demonstrates Superior Tumoricidal Activity and Survival Benefit in Breast Cancer Model
From Zetagen Therapeutics, Inc.
Via Business Wire
News headline image
Zetagen Therapeutics to Present Preliminary Results from Phase 2 Clinical Trial Targeting Metastatic Breast Cancer to Bone at the 2025 San Antonio Breast Cancer Symposium
From Zetagen Therapeutics, Inc.
Via Business Wire
News headline image
Zetagen Therapeutics Secures Composition-of-Matter Patents from USPTO for Novel Breast Cancer Platform
From Zetagen Therapeutics, Inc.
Via Business Wire
News headline image
Zetagen Therapeutics Announces Peer-reviewed Publication of In-Vivo Dose Optimization Findings for ZetaMast™ (Zeta-MBC-005) for Triple Negative Breast Cancer Liver Metastases
From Zetagen Therapeutics, Inc.
Via Business Wire
News headline image
Zetagen Therapeutics Announces Successful Completion of Enrollment in Phase 2a Clinical Study of ZetaMet™ (Zeta-BC-003) Metastatic Breast Cancer
From Zetagen Therapeutics, Inc.
Via Business Wire
News headline image
Zetagen Therapeutics Expands IP Portfolio, Achieving a Milestone of 64 Worldwide Patents in 2024
From Zetagen Therapeutics, Inc.
Via Business Wire
News headline image
Zetagen Therapeutics Shares In-vivo Dose Optimization Data of ZetaMAST™ (Zeta-MBC-005) Metastatic Breast Cancer in Liver
From Zetagen Therapeutics, Inc.
Via Business Wire
News headline image
Zetagen Therapeutics Announces First Patients Enrolled in Phase 2a Clinical Study of ZetaMet™ (Zeta-BC-003) Metastatic Breast Cancer
From Zetagen Therapeutics, Inc.
Via Business Wire
News headline image
New Data Published in JAAOS Demonstrates Breakthrough Therapy ZetaFuse® as a Potential Treatment for Degenerative Disc Disease in Late-Stage Cancer Patients
From Zetagen Therapeutics, Inc.
Via Business Wire
News headline image
Zetagen Therapeutics Secures 9.79 Million USD Series B Funding Raise for Advancement of ZetaMet™ and ZetaMAST™ for Treatment of Metastatic Bone and Soft Tissue Lesions
From Zetagen Therapeutics, Inc.
Via Business Wire
News headline image
ZetaMet™ Receives Health Canada Authorization for Phase 2a Study in Treating Metastatic Bone Lesions
From Zetagen Therapeutics, Inc.
Via Business Wire
News headline image
Zetagen Therapeutics Awarded $2 Million USD Grant from the National Cancer Institute (NCI) for Phase 2 Study of ZetaMet™ for Treatment of Metastatic Bone Cancers
From Zetagen Therapeutics, Inc.
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.